Research
Scientists identify inhibition of a specific enzyme as a promising target to treat pancreatic cancer
The Brief
- A study in The American Journal of Pathology reports that blocking complement factor B (CFB), an enzyme in the alternative complement pathway, halted pancreatic cancer growth.
- The reported effect includes altering the tumour environment, according to the article summary.
- The source describes the finding as a promising target for treatment, not a validated therapy.
Why it matters
The study points to a specific enzyme as a candidate drug target for pancreatic cancer, a disease with limited treatment options, which may guide future preclinical and clinical work.
Who’s affected
- pancreatic cancer researchers
- drug developers working on complement pathway inhibitors
- clinicians following pancreatic cancer research
- #pancreatic cancer
- #complement factor B
- #enzyme inhibition
- #cancer research
- #drug target
Researchers have identified a promising new target in the treatment of pancreatic cancer. A new study in The American Journal of Pathology demonstrates that blocking complement factor B (CFB), a pivotal enzyme in the alternative complement pathway, halts cancer growth and alters…
Timeline
Medical Xpress - latest medical and health news stories
Scientists identify inhibition of a specific enzyme as a promising target to treat pancreatic cancer
Medical Xpress reports the study identifying CFB inhibition as a promising pancreatic cancer target